Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lampalizumab - Genentech

Drug Profile

Lampalizumab - Genentech

Alternative Names: Anti-complement Factor D antibody; Anti-factor D; FCFD4514S; RG7417; RO 5490249; TNX-234

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tanox
  • Developer Genentech
  • Class Anti-inflammatories; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Complement factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dry age-related macular degeneration

Most Recent Events

  • 23 Apr 2019 Roche terminates the phase III CHROMA trial in Dry age-related macular degeneration in USA, Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Hungary, Italy, Mexico, the Netherlands, Peru, Poland, Slovakia, Spain, Switzerland, and the UK (NCT02247479)
  • 21 Aug 2018 Roche terminates the Omaspect phase III trial in Dry age related macular degeneration in USA, Australia, Austria, Belgium, Canada,Denmark, France, Germany, Hungary, Italy, the Netherlands, Peru, Poland, Portugal Slovakia, Spain, Switzerland, Turkey, the United Kingdom (NCT02745119)
  • 21 Feb 2018 Discontinued - Phase-III for Dry age-related macular degeneration in Switzerland, Spain, Slovakia, Poland, Netherlands, Italy, Hungary, Germany, France, Denmark, Belgium, Austria, Australia, USA, Portugal, Russia, United Kingdom (Intravitreous)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top